Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2026-03-26 @ 3:18 PM
Ignite Modification Date:
2026-03-26 @ 3:18 PM
NCT ID:
NCT07466251
Eligibility Criteria:
Inclusion Criteria:
* Age \>=30 and \<=80;2.Acute ischemic stroke within 72 hours of onset (as determined by CT/MRI in conjunction with neurological deficit symptoms)
* Acute ischemic stroke within 72 hours of onset (diagnosed by CT/MRI in conjunction with neurological deficit symptoms)
* NIHSS score of 4-25 at admission
* Imaging studies (CTA/DSA/MRA) support intracranial atherosclerosis as the cause of stroke, meeting one of the following criteria: i. The culprit vessel exhibits intracranial atherosclerotic stenosis (ICAS) with a narrowing degree of 50-99%; ii. The culprit vessel exhibits intracranial atherosclerotic occlusion (ICAS-LVO), with successful recanalization achieved via mechanical thrombectomy (immediate expanded thrombolysis in cerebral infarction \[eTICI\] grade 2b50-3)
* Informed consent signed
Exclusion Criteria:
* Non-atherosclerotic intracranial arterial stenosis (such as arterial dissection, Moyamoya disease, systemic vasculitis, etc.)
* Any identifiable source of cardiogenic embolism (such as atrial fibrillation, mechanical valves, left ventricular thrombus, patent foramen ovale, etc.)
* Imaging findings and clinical presentation suggest that the primary pathophysiology of this event is more consistent with cerebral small vessel disease (e.g., perforator artery occlusion/lacunar infarction)
* Pre-existing disability prior to this ischemic event (modified Rankin Scale ≥ 2 points)
* CT or MRI findings suggest extensive cerebral infarction (e.g., ASPECTS score \< 6 or infarct volume ≥ 70 ml)
* Has undergone or is scheduled to undergo a vascular stent implantation procedure within the next three months
* Any intracranial hemorrhage occurring within 3 months prior to enrollment;
* Intracranial tumors, cerebral aneurysms, or arteriovenous malformations that are assessed as having indications for interventional treatment
* Severe active bleeding tendency or coagulation disorder
* Severe dysfunction of vital organs such as the heart, liver, and kidneys
* Received PCSK9 monoclonal antibody inhibitor therapy within 1 month prior to enrollment or PCSK9 siRNA inhibitor therapy within 6 months prior to enrollment
* A clear contraindication to statins or a history of intolerance to them
* Pregnancy, breastfeeding, or planning pregnancy;14.Currently participating in another study
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
30 Years
Maximum Age:
80 Years
Study:
NCT07466251
Study Brief:
Protocol Section:
NCT07466251